Impact of a Novel, Low-Cost and Sustainable Health Education Program on the Knowledge, Attitudes, and Practices Related to Intestinal Schistosomiasis in School Children in a Hard-to-Reach District of Madagascar
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
ABSTRACT.
Schistosomiasis control requires multisectoral approaches including praziquantel treatment,
access to safe water, sanitation and hygiene, and health education. Community input
can help ensure health education programs are culturally appropriate to effectively
direct protective behavior change. This study reports on the three-stage development
of an education program for Malagasy children, with an impact evaluation on their
knowledge, attitudes, and practices (KAP) related to intestinal schistosomiasis. A
cross-sectional study took place in 2017 with follow-up in 2018 in the hard-to-reach
Marolambo district, Madagascar. A novel schistosomiasis education program (SEP) was
designed in collaboration with researchers, stakeholders, and local community and
included cartoon books, games, songs, puzzles, and blackboard lessons, costing $10
USD per school. KAP questionnaires were completed by 286 children pre-SEP and 273
children post-SEP in 2017, and by 385 and 337 children pre-SEP and post-SEP, respectively,
in 2018. Improvements were observed in responses to all questions between pre- and
post-education answers in 2017 (53–77%,
P < 0.0001) and 2018 (72–98%,
P < 0.0001) and in the pre-education answers between years (53–72%,
P < 0.0001). Praziquantel mass drug administration attendance improved, rising from
64% to 91% (
P < 0.0001), alongside improved latrine use, from 89% to 96% (
P = 0.005). This community-consulted and -engaged SEP resulted in substantial improvements
in children’s understanding of schistosomiasis, with improvements in praziquantel
uptake and latrine use. Socioculturally tailored education programs can help gain
schistosomiasis control. Continued investment in SEP will help promote the future
well-being of children through increased participation in control and treatment activities.
Summary Background How long one lives, how many years of life are spent in good and poor health, and how the population’s state of health and leading causes of disability change over time all have implications for policy, planning, and provision of services. We comparatively assessed the patterns and trends of healthy life expectancy (HALE), which quantifies the number of years of life expected to be lived in good health, and the complementary measure of disability-adjusted life-years (DALYs), a composite measure of disease burden capturing both premature mortality and prevalence and severity of ill health, for 359 diseases and injuries for 195 countries and territories over the past 28 years. Methods We used data for age-specific mortality rates, years of life lost (YLLs) due to premature mortality, and years lived with disability (YLDs) from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 to calculate HALE and DALYs from 1990 to 2017. We calculated HALE using age-specific mortality rates and YLDs per capita for each location, age, sex, and year. We calculated DALYs for 359 causes as the sum of YLLs and YLDs. We assessed how observed HALE and DALYs differed by country and sex from expected trends based on Socio-demographic Index (SDI). We also analysed HALE by decomposing years of life gained into years spent in good health and in poor health, between 1990 and 2017, and extra years lived by females compared with males. Findings Globally, from 1990 to 2017, life expectancy at birth increased by 7·4 years (95% uncertainty interval 7·1–7·8), from 65·6 years (65·3–65·8) in 1990 to 73·0 years (72·7–73·3) in 2017. The increase in years of life varied from 5·1 years (5·0–5·3) in high SDI countries to 12·0 years (11·3–12·8) in low SDI countries. Of the additional years of life expected at birth, 26·3% (20·1–33·1) were expected to be spent in poor health in high SDI countries compared with 11·7% (8·8–15·1) in low-middle SDI countries. HALE at birth increased by 6·3 years (5·9–6·7), from 57·0 years (54·6–59·1) in 1990 to 63·3 years (60·5–65·7) in 2017. The increase varied from 3·8 years (3·4–4·1) in high SDI countries to 10·5 years (9·8–11·2) in low SDI countries. Even larger variations in HALE than these were observed between countries, ranging from 1·0 year (0·4–1·7) in Saint Vincent and the Grenadines (62·4 years [59·9–64·7] in 1990 to 63·5 years [60·9–65·8] in 2017) to 23·7 years (21·9–25·6) in Eritrea (30·7 years [28·9–32·2] in 1990 to 54·4 years [51·5–57·1] in 2017). In most countries, the increase in HALE was smaller than the increase in overall life expectancy, indicating more years lived in poor health. In 180 of 195 countries and territories, females were expected to live longer than males in 2017, with extra years lived varying from 1·4 years (0·6–2·3) in Algeria to 11·9 years (10·9–12·9) in Ukraine. Of the extra years gained, the proportion spent in poor health varied largely across countries, with less than 20% of additional years spent in poor health in Bosnia and Herzegovina, Burundi, and Slovakia, whereas in Bahrain all the extra years were spent in poor health. In 2017, the highest estimate of HALE at birth was in Singapore for both females (75·8 years [72·4–78·7]) and males (72·6 years [69·8–75·0]) and the lowest estimates were in Central African Republic (47·0 years [43·7–50·2] for females and 42·8 years [40·1–45·6] for males). Globally, in 2017, the five leading causes of DALYs were neonatal disorders, ischaemic heart disease, stroke, lower respiratory infections, and chronic obstructive pulmonary disease. Between 1990 and 2017, age-standardised DALY rates decreased by 41·3% (38·8–43·5) for communicable diseases and by 49·8% (47·9–51·6) for neonatal disorders. For non-communicable diseases, global DALYs increased by 40·1% (36·8–43·0), although age-standardised DALY rates decreased by 18·1% (16·0–20·2). Interpretation With increasing life expectancy in most countries, the question of whether the additional years of life gained are spent in good health or poor health has been increasingly relevant because of the potential policy implications, such as health-care provisions and extending retirement ages. In some locations, a large proportion of those additional years are spent in poor health. Large inequalities in HALE and disease burden exist across countries in different SDI quintiles and between sexes. The burden of disabling conditions has serious implications for health system planning and health-related expenditures. Despite the progress made in reducing the burden of communicable diseases and neonatal disorders in low SDI countries, the speed of this progress could be increased by scaling up proven interventions. The global trends among non-communicable diseases indicate that more effort is needed to maximise HALE, such as risk prevention and attention to upstream determinants of health. Funding Bill & Melinda Gates Foundation.
Community-based research in public health focuses on social, structural, and physical environmental inequities through active involvement of community members, organizational representatives, and researchers in all aspects of the research process. Partners contribute their expertise to enhance understanding of a given phenomenon and to integrate the knowledge gained with action to benefit the community involved. This review provides a synthesis of key principles of community-based research, examines its place within the context of different scientific paradigms, discusses rationales for its use, and explores major challenges and facilitating factors and their implications for conducting effective community-based research aimed at improving the public's health.
Title:
The American Journal of Tropical Medicine and Hygiene
Publisher:
The American Society of Tropical Medicine and Hygiene
ISSN
(Print):
0002-9637
ISSN
(Electronic):
1476-1645
Publication date
(Print):
February
2022
Publication date
(Electronic):
10
January
2022
Publication date PMC-release: 10
January
2022
Volume: 106
Issue: 2
Pages: 685-694
Affiliations
[1]North Bristol NHS Trust, Bristol, United Kingdom;
[2]The University of Manchester Faculty of Biology Medicine and Health, Manchester Academic
Health Centre, Manchester, United Kingdom;
[3]Faculté de Médecine, Université d’Antananarivo, Antananarivo, Madagascar;
[4]Department of Clinical Research, London School of Hygiene and Tropical Medicine, London,
United Kingdom;
[5]Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool,
United Kingdom;
[6]World Health Organization, Madagascar Country Office, Antananarivo, Madagascar;
[7]Ministère de la Santé Publique de Madagascar, Antananarivo, Madagascar
Author notes
[*
]Address correspondence to Stephen A. Spencer, Acute Medical Unit, North Bristol NHS
Trust, Southmead Road, Bristol, BS10 5NB, United Kingdom. E-mail:
stephenaspencer@
123456doctors.org.uk
Financial support: This work was supported by Biotechnology and Biological Sciences
Research Council school regional champion funds and Doctoral Training Partnerships
funds awarded to S. M. C.; American Association for the Advancement of Science Leshner
Fellowship funds awarded to S. M. C.; British Society of Immunology Communicating
Immunology Grants awarded to S. A. S., S. M. C., K. H., and J. M. StJ. P.; Scientific
Exploration Society Rivers Award for Health and Humanities awarded to S. A. S.; and
Royal Geographical Society Geographical Fieldwork Grant awarded to S. A. S.
This is an open-access article distributed under the terms of the
Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided
the original author and source are credited.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.